On September 18, 2020 BioEclipse Therapeutics, a private clinical-stage biopharmaceutical company developing first-in-class, curative immuno-oncology therapeutics, reported that its CEO and founder Pamela Contag, Ph.D., and CFO Ben Carter will participate in the Sachs 20th Annual Biotech in Europe Forum, taking place September 21–24, 2020 via a virtual platform (Press release, BioEclipse Therapeutics, SEP 18, 2020, View Source [SID1234565369]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Contag will host virtual one-on-one meetings with investors and potential partners to discuss BioEclipse’s business strategy and highlight recent corporate achievements, as well as anticipated milestones in its clinical program for CRX100, BioEclipse’s lead investigative candidate. Institutional investors are invited to request meeting times.

To schedule a one-on-one meeting, please contact Dr. Contag or Mr. Carter at BioEclipse Therapeutics.

CRX100 is an intravenously delivered cancer therapy designed to target and destroy multiple cancer types and to prevent disease recurrence. It only targets tumor cells, leaving healthy tissue untouched, but it has the ability to reach tumors throughout the body. This means CRX100 holds promise for metastatic disease treatment with limited toxicity. BioEclipse plans to initiate a Phase 1 clinical trial in therapy-refractory solid tumors before year end.